Search FHI 360

Start a New Search

Search within these results

HealthArticleResearch servicesHIV preventionHIV and AIDS

7 Results Found

News

Final results of FEM-PrEP HIV-prevention study indicate great attention to adherence will be required in PrEP programs

RESEARCH TRIANGLE PARK, NC — Results of the FHI 360 FEM-PrEP HIV-prevention trial reinforce the key role of adherence in HIV-prevention studies and the need to determine better approaches to support adherence in future pre-exposure prophylaxis (PrEP...
News

'Science' names HIV prevention trial as breakthrough of the year

RESEARCH TRIANGLE PARK, NC — Today, Science named the HIV Prevention Trials Network (HPTN) 052 study "Breakthrough of the Year." FHI 360 congratulates our HPTN 052 collaborating partners on this important achievement. This is the second year in a...
News

VOICE HIV prevention trial discontinues Tenofovir gel arm

RESEARCH TRIANGLE PARK, NC — The Microbicides Trials Network (MTN) announced today that it will discontinue testing tenofovir vaginal gel in the HIV prevention trial VOICE (Vaginal and Oral Interventions to Control the Epidemic). This decision came...
News

HPTN 043 Project Accept study published in the Lancet Infectious Diseases demonstrates that community mobilization boosts HIV testing rates in developing countries

The addition of community mobilization activities and support services to a mobile HIV counseling and testing program can greatly improve the rates of initial and repeat testing in remote rural communities, according to new research supported by the...
Announcement

FHI selected as preferred provider to a consortium of product development partnerships

RESEARCH TRIANGLE PARK, NC — FHI has been selected as one of six preferred providers offering their clinical research expertise to a consortium of 14 global health Product Development Partnerships (PDPs). The consortium of PDPs is working to develop...
Announcement

FHI congratulates iPrEx team on study showing reduced risk of HIV infection in men

FHI welcomes the exciting proof of concept study results for oral Truvada pre-exposure prophylaxis (PrEP) therapy, published online today in the New England Journal of Medicine. The iPrEx study found that the daily use of an antiretroviral (ARV)...
News

FHI 360 statement on the Heffron et al study and hormonal contraceptives and HIV risk

On October 4, 2011 The Lancet Infectious Diseases published an article by Renee Heffron and a group of researchers at the University of Washington. The study was conducted among nearly 3,800 HIV-serodiscordant couples (in which one partner is HIV...

You are here

Search FHI 360

Practice Areas

Services

Content Types

Expertise Areas

Countries

Article Types

Final results of FEM-PrEP HIV-prevention study indicate great attention to adherence will be required in PrEP programs

'Science' names HIV prevention trial as breakthrough of the year

VOICE HIV prevention trial discontinues Tenofovir gel arm

HPTN 043 Project Accept study published in the Lancet Infectious Diseases demonstrates that community mobilization boosts HIV testing rates in developing countries

FHI selected as preferred provider to a consortium of product development partnerships

FHI congratulates iPrEx team on study showing reduced risk of HIV infection in men

FHI 360 statement on the Heffron et al study and hormonal contraceptives and HIV risk